Emergency Use Authorization for Remdesivir and Its Potential Implications
- PDF / 553,615 Bytes
- 2 Pages / 595.276 x 790.866 pts Page_size
- 25 Downloads / 206 Views
COMMENTARY
Emergency Use Authorization for Remdesivir and Its Potential Implications Cassius Iyad Ochoa Chaar, MD, MS1 · Robert Makuch, PhD2 Received: 25 June 2020 / Accepted: 24 August 2020 © The Drug Information Association, Inc 2020
The COVID-19 pandemic is unraveling as the most devastating disease impacting humanity. The repercussions extend far beyond the sobering 15.3 million infections and 620,000 deaths worldwide, into a global economic free fall, exponential rise of unemployment, and disruption of social bonds [1]. At the center of this pandemic is a disease with no antidote or vaccine. The interim analysis of the NIH sponsored Adaptive COVID-19 Treatment Trial (ACTT) on April 27th, brought a spark of hope. The published results showed that treatment with remdesivir significantly decreased the time to recovery to 11 days compared to 15 days with placebo, a statistically significant reduction of 31% (P
Data Loading...
